Infliximab (IFX) is a chimeric anti-TNFa IgG1 antibody approved for the treatment of immune mediated diseases, namely Crohn’s disease (CD), ulcerative colitis (UC), spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA) and chronic plaque psoriasis (PsO). This evidence concerns the gene TNF and rheumatoid arthritis.